Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-379 in Healthy Volunteers
NCT05952219Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CKD-379 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Status: unknown.
02
Drugs
CKD-379
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05952219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952219.